双特异性 T 细胞接合剂 (BiTE) 等新型 T 细胞免疫疗法正在成为前列腺癌有前景的治疗策略。 BiTE 是工程化的双特异性抗体，含有两个不同的结合域，允许同时结合肿瘤相关抗原 (TAA) 以及免疫效应细胞，从而促进针对癌细胞的免疫反应。前列腺癌富含肿瘤相关抗原，例如但不限于 PSMA、PSCA、hK2 和 STEAP1，并且在前列腺癌疾病空间内使用 T 细胞重定向 BiTE 具有强有力的生物学原理。临床研究中采用的早期 BiTE 结构已表现出有意义的抗肿瘤活性，但与药物递送、免疫原性和治疗相关不良反应相关的挑战限制了其成功。新型 BiTE 结构的持续开发将继续解决这些障碍，并在功效和安全性方面产生有希望的结果。本综述将重点介绍针对晚期前列腺癌患者的 BiTE 疗法的一些最新进展，以及正在进行临床评估的围绕 BiTE 结构的不断变化的数据。

Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as well as immune effector cells, thus promoting an immune response against cancer cells. Prostate cancer is rich in tumor associated antigens such as, but not limited to, PSMA, PSCA, hK2, and STEAP1 and there is strong biologic rationale for employment of T-cell redirecting BiTEs within the prostate cancer disease space. Early generation BiTE constructs employed in clinical study have demonstrated meaningful antitumor activity, but challenges related to drug delivery, immunogenicity, and treatment-associated adverse effects limited their success. The ongoing development of novel BiTE constructs continues to address these barriers and to yield promising results in terms of efficacy and safety. This review will highlight some of most recent developments of BiTE therapies for patients with advanced prostate cancer and the evolving data surrounding BiTE constructs undergoing clinical evaluation.